<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062710</url>
  </required_header>
  <id_info>
    <org_study_id>MMC-IRB-13-10-170</org_study_id>
    <nct_id>NCT02062710</nct_id>
  </id_info>
  <brief_title>Antitussive Effect of a Naturally Flavored Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo</brief_title>
  <official_title>Antitussive Effect of a Naturally Flavored, Multi-Component Syrup Containing Diphenhydramine, Compared With Dextromethorphan and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antitussive (cough-suppressing) effects of two
      liquid medications: a combination of diphenhydramine and phenylephrine in a naturally cocoa
      flavoring, and, dextromethorphan syrup, compared with placebo.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cough Reflex Sensitivity to Capsaicin</measure>
    <time_frame>2 hours after study drug administration</time_frame>
    <description>increase in C5 (decrease in cough reflex sensitivity). Capsaicin cough challenge involves subjects breathing in incremental doubling concentrations of aerosolized capsaicin, 1 minute apart, until the concentration of capsaicin (micromolar) inducing 5 or more coughs (C5) is reached.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Cough Reflex Sensitivity</condition>
  <arm_group>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A). Period 2: dextromethorphan syrup 30 mg (treatment B); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C).
Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: single oral doce of diphenhydramine 25 mg and phenylephrine 10 mg, in naturally-flavored cocoa syrup (treatment A); Period 2: placebo liquid, dextrose in watwer, 20 mL (treatment C); Period 3: dextromethorphan syrup 30 mg (treatment B).
Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: dextromethorphan syrup 30 mg (treatment B); Period 2: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg, in a naturally-flavored cocoa syrup (treatment A); Period 3: placebo liquid, dextrose in water, 20 mL (treatment C). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: dextromethorphan 30 mg syrup (treatment B); Period 2: placebo liquid, dextrose in water, 20 mL (treatment C); Period 3: single dose of oral diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A).
Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A); Period 3: dextromethorphan 30 mg syrup (treatment B). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C, B, then A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received the following: Period 1: placebo liquid, dextrose in water, 20 mL (treatment C); Period 2: dextromethorphan 30 mg syrup (treatment B); Period 3: a single oral dose of diphenhydramine 25 mg and phenylephrine 10 mg in a naturally-flavored cocoa syrup (treatment A). Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion. Each dosing period separated by 1-2 day washout period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo</intervention_name>
    <description>diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan</intervention_name>
    <description>diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo</intervention_name>
    <description>dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa</intervention_name>
    <description>dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan</intervention_name>
    <description>placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa</intervention_name>
    <description>placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg</description>
    <arm_group_label>A, B, then C</arm_group_label>
    <arm_group_label>A, C, then B</arm_group_label>
    <arm_group_label>B, A, then C</arm_group_label>
    <arm_group_label>B, C, then A</arm_group_label>
    <arm_group_label>C, A, then B</arm_group_label>
    <arm_group_label>C, B, then A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy adult nonsmokers

          -  onset of acute, viral upper respiratory tract infection (common cold) within 72 hours
             of enrollment

        Exclusion Criteria:

          -  smokers

          -  history of asthma or other respiratory disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Einstein Division/Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2014</study_first_posted>
  <results_first_submitted>September 16, 2014</results_first_submitted>
  <results_first_submitted_qc>April 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 28, 2015</results_first_posted>
  <last_update_submitted>February 26, 2018</last_update_submitted>
  <last_update_submitted_qc>February 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Montefiore Medical Center</investigator_affiliation>
    <investigator_full_name>Peter Dicpinigaitis</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cough</keyword>
  <keyword>cough reflex</keyword>
  <keyword>capsaicin</keyword>
  <keyword>diphenhydramine</keyword>
  <keyword>phenylephrine</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>placebo</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylephrine</mesh_term>
    <mesh_term>Oxymetazoline</mesh_term>
    <mesh_term>Phenylpropanolamine</mesh_term>
    <mesh_term>Chlorpheniramine, phenylpropanolamine drug combination</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Capsaicin</mesh_term>
    <mesh_term>Guaifenesin</mesh_term>
    <mesh_term>Antitussive Agents</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diphenhydramine/Phen/Cocoa, Dextromethorphan, Then Placebo</title>
          <description>Diphenhydramine 25 mg, phenylephrine 10 mg, in naturally-flavored cocoa syrup; then dextromethorphan 30 mg; then placebo.
Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Washout 1-2 days between each of the 3 dosing periods.</description>
        </group>
        <group group_id="P2">
          <title>Diphenhydramine/Phenylephrine/Cocoa, Then Placebo, Then Dextro</title>
          <description>diphenhydramine 25 mg and phenylephrine 10 mg; then placebo; then dextromethorphan 30 mg.
Intervention: capsaicin cough challenge testing after study drug ingestion</description>
        </group>
        <group group_id="P3">
          <title>Dextromethorphan, Diphenhydramine/Phenylephrine/Cocoa, Then pl</title>
          <description>dextromethorphan 30 mg, then diphenhydramine/phenylephrine/cocoa, then placebo. Intervention: capsaicin cough challeneg 2 hours after study drug ingestion</description>
        </group>
        <group group_id="P4">
          <title>Dextromethorphan, Placebo, Then Diphenhydramine/Phenylephrine/</title>
          <description>dextromethorphan 30 mg, then placebo, then diphenhydramine 25 mg and phenylephrine 10 mg.
Intervention: capsaicin cough challenge 2 hours after study drug ingestion. Washout period 1-2 days between each of the 3 dosing periods</description>
        </group>
        <group group_id="P5">
          <title>Placebo, Diphenhydramine/Phenylephrine/Cocoa, Then Dextrometho</title>
          <description>placebo, then diphenhydramine 25 mg and phenylephrine 10 mg, then dextromethorphan 30 mg.
Intervention: capsaicin cough challenge 2 hours after study drug administration.
Washout period 1-2 days after each of the 3 dosing periods</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Dextromethorphan, Then Diphenhydramine/Phenylephrine/</title>
          <description>placebo, then dextromethorphan 30 mg, then diphenhydramine 25 mg and phenylephrine 10 mg.
Intervention: capsaicin cough challenge 2 hours after study drug administration.
Washout period 1-2 days after each of the 3 dosing periods.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3">3 of total 22 subjects randomized to receive the 3 study drugs in this particular sequence</participants>
                <participants group_id="P2" count="4">4 of the total 22 subjects randomized to receive the 3 study drugs in this particular sequence</participants>
                <participants group_id="P3" count="5">5 of total of 22 subjects randomized to receive the 3 study drugs in this particular sequence</participants>
                <participants group_id="P4" count="3">3 of 22 subjects randomized to receive the 3 study drugs in this particular sequence</participants>
                <participants group_id="P5" count="3">3 of 22 subjects randomized to receive the 3 study drugs in this aprticular sequence</participants>
                <participants group_id="P6" count="4">4 of 22 subjects randomized to receive the 3 study drugs in this particular sequence</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Diphenhydramine/Phenylephrine/Cocoa, Dextromethorphan,Placebo</title>
          <description>Diphenhydramine 25 mg, phenylephrine 10 mg, in naturally-flavored cocoa syrup; dextromethorphan; placebo.
Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Phenylephrine: 10 mg dose phenylephrine
Diphenhydramine: 25 mg dose diphenhydramine
Dextromethorphan: 30 mg dose dextromethorphan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cough Reflex Sensitivity to Capsaicin</title>
        <description>increase in C5 (decrease in cough reflex sensitivity). Capsaicin cough challenge involves subjects breathing in incremental doubling concentrations of aerosolized capsaicin, 1 minute apart, until the concentration of capsaicin (micromolar) inducing 5 or more coughs (C5) is reached.</description>
        <time_frame>2 hours after study drug administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Diphenhydramine/Phenylephrine/Cocoa</title>
            <description>Diphenhydramine 25 mg, phenylephrine 10 mg, in naturally-flavored cocoa syrup. Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Phenylephrine: 10 mg dose phenylephrine
Diphenhydramine: 25 mg dose diphenhydramine</description>
          </group>
          <group group_id="O2">
            <title>Dextromethorphan</title>
            <description>Dextromethorphan syrup, 30 mg dose. Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Dextromethorphan: 30 mg dose dextromethorphan</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo liquid, dextrose in water, 20 mL</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cough Reflex Sensitivity to Capsaicin</title>
          <description>increase in C5 (decrease in cough reflex sensitivity). Capsaicin cough challenge involves subjects breathing in incremental doubling concentrations of aerosolized capsaicin, 1 minute apart, until the concentration of capsaicin (micromolar) inducing 5 or more coughs (C5) is reached.</description>
          <units>log C5 (uM)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.16"/>
                    <measurement group_id="O2" value="0.80" spread="0.18"/>
                    <measurement group_id="O3" value="0.57" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Diphenhydramine/Phenylephrine/Cocoa</title>
          <description>Diphenhydramine 25 mg, phenylephrine 10 mg, in naturally-flavored cocoa syrup. Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Phenylephrine: 10 mg dose phenylephrine
Diphenhydramine: 25 mg dose diphenhydramine</description>
        </group>
        <group group_id="E2">
          <title>Dextromethorphan</title>
          <description>Dextromethorphan syrup, 30 mg dose. Intervention: capsaicin cough challenge testing 2 hours after study drug ingestion.
Dextromethorphan: 30 mg dose dextromethorphan</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>placebo liquid, dextrose in water, 20 mL</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Peter Dicpinigaitis, MD</name_or_title>
      <organization>Montefiore Medcial Center</organization>
      <phone>718-904-2676</phone>
      <email>pdicpini@montefiore.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

